References
- Ocular Therapeutix™ reports inducement grant under Nasdaq listing rule 5635(C)(4). (2019). https://ocutx.gcs-web.com/news-releases/news-release-details/ocular-therapeutixtm-reports-inducement-grant-under-nasdaq-0
- Orum Therapeutics announces $30 million series B financing to advance cell-penetrating, cell-specific antibody technology for novel therapeutics. (2019). www.orumrx.com/news/2019/7/17/orum-therapeutics-announces-30-million-series-b-financing-to-advance-cell-penetrating-cell-specific-antibody-technology-for-novel-therapeutics
- ArunA Bio raises $13 million in common stock financing. (2019). www.businesswire.com/news/home/20190724005130/en/ArunA-Bio-Raises-13-Million-Common-Stock
- Orexo . Orexo interim report Q2. (2019). https://orexo.com/investors/reports-presentations-and-audiocasts?releaseId=BA7CEAA426B38E21
- Glaukos announces global licensing agreement with Intratus, Inc. (2019). http://investors.glaukos.com/investors/press-releases/press-release-details/2019/Glaukos-Announces-Global-Licensing-Agreement-With-Intratus-Inc/default.aspx
- BIOCORP enters exclusive negotiations with SANOFI to use their Mallya connected device with Sanofi's integrated diabetes care platform. (2019). https://biocorpsys.com/en/biocorp-enters-exclusive-negotiations-with-sanofi-to-use-their-mallya-connected-device-with-sanofis-integrated-diabetes-care-platform/
- Investigational subcutaneous formulation of Vedolizumab meets primary endpoint in achieving clinical remission at week 52 in patients with moderately to severely active Crohn's disease. (2019). www.takeda.com/newsroom/newsreleases/2019/investigational-subcutaneous-formulation-of-vedolizumab-meets-primary-endpoint-in-achieving-clinical-remission-at-week-52-in-patients-with-moderately-to-severely-active-crohns-disease/
- Oyster point pharma announces enrollment of first subject in Phase III clinical trial of nasal spray for dry eye disease. (2019). https://investors.oysterpointrx.com/node/6126/pdf
- Vazquez-Rios AJ , Molina-CrespoA , BouzoBL , Lopez-LopezR , Moreno-BuenoG , dela Fuente M. Exosome-mimetic nanoplatforms for targeted cancer drug delivery. J. Nanobiotechnol.17(1), 85–100 (2019).
- Navya PN , KaphleA , SrinivasSP , BhargavaSK , RotelloVM , DaimaHK. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg.6(1), 2353 (2019).